This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

Damora Therapeutics recently overhauled its leadership team, appointing Jennifer Jarrett as President and CEO and naming Brian Burkavage as principal financial and accounting officer following the planned departure of CFO Lori Firmani effective May 1, 2026. The combination of Jarrett’s oncology and investment banking background with a new finance lead points to a sharpened focus on advancing DMR-001 and preparing for future commercialization. Next, we examine how this leadership reshaping,...

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive […]

CFO transition puts Damora Therapeutics (DMRA) in focus Damora Therapeutics (NasdaqCM:DMRA) is back on investors’ radar after the company announced that Lori Firmani has stepped down as Chief Financial Officer. Brian Burkavage has taken over the role. See our latest analysis for Damora Therapeutics. The CFO transition comes after a period of strong momentum, with a year to date share price return of 18.84% and a 1 year total shareholder return of around 7x, even though the 3 and 5 year total...

Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin target

Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Damora Therapeutics recently appointed Jennifer Jarrett as its new Chief Executive Officer and President, overhauled several Board seats, and issued sizeable equity awards tied to these leadership changes. The combination of Jarrett’s deep biopharma and capital markets background with new directors from Blueprint Medicines and Spyre Therapeutics points to a potentially different approach to funding and portfolio execution. Next, we’ll examine how installing Jennifer Jarrett as CEO and...